Filing Flows

Filing Flows › Supernus Pharmaceuticals (SUPN) › Next earnings date

Supernus Pharmaceuticals (SUPN) earnings: beat the estimate

Supernus Pharmaceuticals (SUPN) reported on Oct 29, 2026 and beat the EPS estimate: $1.32 against $1.13 (+17.2%). Revenue was $227M for Q3 2026, +18% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+17.2% vs estimate
Beat rate80%

The last report

Supernus Pharmaceuticals reported revenue of $227M for the third quarter 2026 (+18% Y/Y), net earnings $20.9M: Net product sales $179M, ONAPGO $17.1M, Trokendi XR $10.2M, Oxtellar XR $8.0M. How it makes money → · Every quarter →

Supernus Pharmaceuticals: EPS against the estimate, last 5 reportsSupernus Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported$0.82$0.61Nov 25$0.67$0.82Feb 26$0.66$0.96Apr 26$0.92$1.15Aug 26$1.13$1.32Oct 26
Latest (Oct 26): Estimate $1.13, Reported $1.32.

Supernus Pharmaceuticals' latest quarter

Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.

Questions

Did Supernus Pharmaceuticals beat earnings?

Supernus Pharmaceuticals (SUPN) reported on Oct 29, 2026 and beat the EPS estimate: $1.32 against $1.13 (+17.2%).

When does SUPN report earnings?

The next date is not set yet.

Does Supernus Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.